Kava
Viewing r2 — May 13, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Kava (Piper methysticum G.Forst., Piperaceae) is a Pacific Island root beverage consumed for its anxiolytic and sedative properties. Its pharmacology is driven by kavalactones — six substituted α-pyrones dominated by kavain.[1][2] Kavain produces its principal effects by potentiating GABAA receptors at a site distinct from the benzodiazepine binding pocket, yielding anxiolysis without benzodiazepine-class cognitive impairment.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Pacific Island cultures have consumed kava in ceremonial, social, and medicinal contexts for at least 3,000 years, with the plant first scientifically described by Georg Forster in 1786.[2][4] Commercial kava extracts achieved top herbal medicine sales in Europe by the 1990s before regulatory bans in approximately twelve countries following hepatotoxicity case reports beginning in 1999.[5] Germany's ban was definitively lifted in June 2024,[6] and a growing kava bar culture has emerged in the United States.[7]
Subjective effects include anxiolysis, skeletal muscle relaxation, mild euphoria, sociability enhancement, and perioral numbness. Traditional aqueous beverages produce a shorter, clear-headed sociable experience, while standardized extracts provide sustained anxiolysis — and tudei (non-noble) cultivars produce heavier sedation and nausea lasting up to two days.[2] Characteristic unsought effects include gastrointestinal upset, headache, dizziness, and fatigue.[8]
Dependence risk at therapeutic doses is low, with "reverse tolerance" described in traditional contexts,[2] though one severe GABAergic withdrawal case has been documented.[9] Hepatotoxicity is the primary safety concern — approximately 100 case reports globally, predominantly linked to organic solvent extracts and non-noble cultivars[10] — and herb–drug interactions with benzodiazepines carry potentially life-threatening risk.[11] Multiple randomized controlled trials support anxiolytic efficacy,[12][8] but the hepatotoxicity mechanism remains unresolved and no harmonized international quality standard exists.
History[edit]
Traditional use in the Pacific
Kava consumption in Pacific Island cultures extends at least 3,000 years, supported by archaeological evidence and linguistic reconstruction tracing the plant's origin to Vanuatu or the broader Melanesian region.[2] The beverage occupies a central role in social, ceremonial, religious, and political life across Melanesia, Polynesia, and Micronesia — documented uses include community gatherings, dispute resolution, welcoming of guests, communication with ancestors, and medicinal applications for anxiety, insomnia, and pain.[1]
Traditional preparation involved chewing fresh root, mixing the masticated material with water, and straining through plant fiber.[2] Later methods substituted stone pounding or mechanical grinding. The resulting opaque, tan-brown liquid is consumed from coconut shells.
Western discovery and commercialization
Georg Forster formally described and named Piper methysticum in 1786 in De Plantis Esculentis Insularum Oceani Australis, based on specimens from Captain Cook's second Pacific voyage (1772–1775).[4] The specific epithet methysticum derives from Latin for "intoxicating." Modern phytochemical characterization of kavalactones proceeded through the 1960s–1980s.[1]
By the 1990s, commercial kava extracts — notably the acetonic extract WS1490 — had reached top-10 herbal medicine sales in Germany and across Europe and North America.[13] The Cochrane Collaboration published reviews affirming anxiolytic efficacy in 2000 and 2002.[14][12]
Regulatory crisis and modern era
Case reports of severe hepatotoxicity appeared beginning in 1999–2001,[15][16] prompting regulatory bans in approximately twelve countries including Germany, France, the United Kingdom, Canada, and Australia.[17] Vanuatu enacted the Kava Act in 2002, defining noble cultivar standards and restricting exports to approved varieties.[18]
German administrative courts began overturning the national ban circa 2013–2015, ruling the restriction "inappropriate and even associated with an increased risk due to higher risk inherent to therapeutic alternatives".[5] The Cologne Administrative Court definitively lifted the ban on June 18, 2024.[6] A landmark 16-week randomized controlled trial for generalized anxiety disorder was published in 2020,[8] and a growing kava bar culture has emerged in the United States — particularly in Florida and Pacific coast states.[7]
Botanical Overview[edit]
Piper methysticum G.Forst. belongs to the pepper family (Piperaceae), a large tropical family that includes black pepper (Piper nigrum). The species is a dioecious perennial shrub; its specific epithet, "intoxicating," reflects the sedative properties of its root system. Kava is exclusively a cultivated plant — it is sterile and does not reproduce sexually in the wild, propagated solely through stem cuttings.[2]
The plant's native range spans the western Pacific, with Vanuatu and the broader Melanesian archipelago identified as the centre of origin.[2] It grows in humid tropical lowland conditions, thriving in well-drained, fertile volcanic soils at elevations below approximately 300 metres. Today kava is cultivated commercially across Vanuatu, Fiji, Tonga, Samoa, and Hawai'i.
Kava grows as a robust, erect shrub reaching 2–3 metres in height, with large, heart-shaped (cordate) leaves on smooth green stems with prominent nodes. The root system — a dense mass of lateral roots and central rhizome — is the harvested portion. Mature plants are typically harvested at 3–5 years of age; the Vanuatu Kava Act specifies a minimum 5-year harvest age for export-grade material.[18]
The distinction between noble and non-noble (tudei) cultivars is critical for both safety and effect quality. Noble cultivars — the only varieties approved for export under Vanuatu law — produce a clear-headed, sociable experience. Tudei cultivars, visually indistinguishable from noble varieties,[19][20] contain elevated levels of dihydromethysticin and flavokavain B and produce heavy sedation, nausea, and residual lethargy lasting up to two days.[2]
Alkaloid Profile[edit]
Kava's psychoactive properties derive from kavalactones — a family of substituted α-pyrones that account for approximately 96% of the lipid resin in dried root material.[1][2] Six major kavalactones dominate: kavain, dihydrokavain, methysticin, dihydromethysticin, desmethoxyyangonin, and yangonin. Kavain is typically the most abundant, comprising roughly 44% of extract content, and serves as the primary driver of GABA-A potentiation.[3]
The kavalactones function as a pharmacological ensemble rather than through any single constituent. Kavain and dihydromethysticin show additive effects on glutamate-mediated field potentials in hippocampal tissue,[21] and whole-extract co-administration triples kavain's plasma exposure in animal models through self-inhibition of CYP metabolism[22] — suggesting that the extract matrix meaningfully alters individual kavalactone pharmacokinetics. Whether this entourage effect extends to clinical anxiolytic outcomes in humans remains uncharacterized in controlled studies.
Flavokavain B, a chalcone rather than a true kavalactone, warrants specific mention as a safety-relevant constituent. It is present at higher concentrations in non-noble (tudei) cultivars and in organic solvent extracts, and has demonstrated cytotoxicity in liver cell models via oxidative stress pathways.[23] Pipermethystine, an alkaloid concentrated in aerial plant material (leaves, stems, peelings), produced 90% hepatocyte death at high concentrations in vitro via mitochondrial apoptosis.[17] Both compounds are implicated in competing hepatotoxicity hypotheses.
Kavalactone concentrations vary significantly across cultivars, plant parts, harvest age, and preparation method.[2] Noble cultivars generally show higher kavain-to-dihydromethysticin ratios than tudei varieties. Commercial products show significant discrepancy between labeled and actual kavalactone content,[2] and no internationally harmonized analytical standard governs kavalactone quantification in consumer products.
Neuroscience[edit]
Receptor targets and mechanism
Kava's anxiolytic profile results from polypharmacological activity across multiple receptor systems. Kavain directly potentiates GABAA receptors, with greater effect at extrasynaptic α4β2δ receptors than at synaptic subtypes.[3] This action is not blocked by flumazenil, confirming a binding site distinct from benzodiazepines — instead overlapping with the general anesthetic site.[3] Additional targets include voltage-gated sodium and calcium channel blockade, NMDA antagonism in hippocampal circuits,[21] and reversible MAO-B inhibition contributing to elevated dopamine levels.[24]
Neuroimaging and downstream effects
An 8-week randomized controlled trial using proton magnetic resonance spectroscopy found decreased GABA levels in the dorsal anterior cingulate cortex following kava treatment at 120 mg kavalactones twice daily.[25] Peripheral gene expression analysis from the same cohort showed decreased GABAA rho subunit expression.[26] Noradrenaline and dopamine reuptake inhibitor has also been documented for several kavalactones.[24]
Three puzzles remain unresolved. First, "reverse tolerance" — regular users requiring less kava over time — has no established pharmacological mechanism and runs counter to typical receptor-mediated tolerance.[2] Second, no formal human oral bioavailability study has been published for any individual kavalactone. Third, the relative contributions of individual kavalactones versus their combined action to the overall anxiolytic effect remain uncharacterized in controlled human studies.
Subjective Effects[edit]
Kava's experiential character is shaped more by preparation and cultivar than by dose alone. Traditional aqueous beverages from noble cultivars produce a distinctively clear-headed sociability with prominent muscle relaxation and perioral numbness — relaxing without sedating at moderate intake. Standardized pharmaceutical extracts emphasize sustained anxiolysis with less of the acute social dimension, while tudei cultivars produce a qualitatively heavier experience dominated by sedation and nausea. Set and setting interact substantially with these preparation differences: the communal context of traditional ceremony amplifies the prosocial qualities.
Pharmacologically, kava sits between benzodiazepines and alcohol as a GABAergic anxiolytic, but diverges from both. It does not produce the cognitive impairment or amnestic effects of benzodiazepines at therapeutic doses, and does not impair driving performance at clinical doses where oxazepam does.[27] Compared to alcohol, kava produces anxiolysis and muscle relaxation without disinhibition-driven behavioral escalation or next-day hangover — though non-noble cultivars partially erode this advantage.
Effect Grid
Clear anxiety suppression and muscle relaxation define this tier. Sociability enhancement becomes a prominent feature — conversation flows freely, social inhibition decreases, and mild cognitive euphoria may produce warmth and contentment. Perioral and lingual numbness is well-established.
Bodily heaviness is moderate; the limbs feel loose and relaxed. Spontaneous body sensations include warmth, tingling, and occasional tactile euphoria. Pain suppression is noticeable. Motor control remains adequate but slightly softened. No significant cognitive impairment occurs at this level — this is the 'clear-headed relaxation' kava is known for.
Effects are clearly distinguishable from baseline and last 2–4 hours with traditional preparations. This tier encompasses the clinical therapeutic range (120–240 mg kavalactones) used in published RCTs.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Music enhancement · Visual haze / noise · Dreaming enhancement · After-images · Color enhancement · Visual processing suppression
Color enhancement · Visual processing suppression
Body high · Spontaneous body sensations · Pain suppression · Tactile euphoria · Dizziness · Nausea · Physical fatigue · Headache · Salivation · Sexual arousal suppression · Nystagmus (eye wobbles) · Vomiting · Sexual arousal enhancement
Dizziness · Nausea · Physical fatigue · Headache · Salivation · Sexual arousal suppression · Nystagmus (eye wobbles) · Vomiting · Sexual arousal enhancement
Information processing suppression · Memory suppression · Humor enhancement · Confusion · Language suppression
Language suppression
Compulsive behavior reduction
Timeline · by preparation
Preparations[edit]
Traditional aqueous beverage
The oldest and most widely consumed form. Fresh or dried root is ground, kneaded in water, and strained through cloth or plant fiber.[2] Kavalactone content varies with root quality, water ratio, and kneading duration, but a typical serving shell contains approximately 150–250 mg of kavalactones. Onset occurs within 20–30 minutes; duration is 2–4 hours. The experience is characterized by clear-headed sociability, muscle relaxation, and perioral numbness. The aqueous method extracts kavalactones less efficiently than organic solvents, which proponents cite as a protective factor against hepatotoxicity — though aqueous preparations are not free of hepatotoxic risk.[28]
Standardized extracts (capsules and tablets)
Commercial kava supplements typically contain acetonic or ethanolic extracts standardized to 30–70% kavalactones. Clinical trials have most commonly used doses of 120–240 mg kavalactones per day.[8] Onset is 30–60 minutes; duration extends to 4–8 hours. The effect profile emphasizes sustained anxiolysis over the acute sociable character of aqueous preparations. Organic solvent extracts are more strongly associated with hepatotoxicity case reports than aqueous preparations.[10]
Kava bar beverages
Kava bars in the United States and elsewhere[7] typically serve aqueous preparations from noble cultivar root powder, often blended or shaken with water and strained to order. Kavalactone content per serving varies significantly depending on the bar's recipe and root source. The experience profile resembles traditional aqueous preparations — sociable, relaxing, and relatively short-acting. Some establishments also serve concentrated "shots" with higher kavalactone loads per volume.
Instant and micronized kava
Dehydrated aqueous extracts or finely milled root powder designed to be stirred directly into water without straining. Kavalactone content per gram is generally higher than traditional grind due to reduced fiber content. Onset and duration approximate traditional aqueous preparations. Potency varies significantly between products and batches.[2]
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- benzodiazepines · alcohol
Toxicity
Hepatotoxicity is the primary toxicity concern. Approximately 100 case reports of liver injury have been documented globally, predominantly between 1999 and 2010, associated primarily with commercial organic solvent (acetonic or ethanolic) extracts.[10][29] Outcomes have ranged from mild hepatic enzyme elevation to acute liver failure requiring transplantation[30] and death. A critical analysis of 26 suspected cases found firm causality difficult to establish in the majority.[31]
Multiple competing hepatotoxicity mechanisms have been proposed, none definitively established[32]:
- Flavokavain B — cytotoxicity via oxidative stress pathways in liver cells; elevated in non-noble cultivars and organic solvent extracts[23]
- Pipermethystine from aerial plant material — mitochondrial apoptosis in hepatocytes at high concentrations[17]
- Reactive metabolite formation — kavalactone glutathione conjugates (mercapturates) detected in human urine[32]
- Mold hepatotoxins — aflatoxins and ochratoxin A from Aspergillus contamination of poorly stored kava[20][33]
- CYP2D6 poor metabolizer phenotype as an idiosyncratic susceptibility factor[15]
The hypothesis that hepatotoxicity occurred only with organic solvent extracts and not traditional aqueous preparations has been contested by documented liver injury from traditional aqueous kava.[28][29] The rate with traditional noble cultivar aqueous preparations in Pacific populations nevertheless appears substantially lower.
Risk factors include organic solvent extraction, non-noble cultivars, aerial plant material inclusion, concurrent alcohol use, concurrent hepatotoxic medications, CYP2D6 poor metabolizer status, mold-contaminated raw material, and pre-existing liver disease.[32][15]
Contaminant and adulterant risk: Commercial kava products carry several preparation-specific contamination vectors. Non-noble cultivar substitution — visually undetectable — introduces elevated flavokavain B and dihydromethysticin.[19][20] Aerial plant material contamination introduces pipermethystine, which is minimally present in peeled root.[17] Mycotoxins (aflatoxins B1, B2, G1, G2, and ochratoxin A) from Aspergillus mold occur in improperly dried or stored material.[20] Labeled kavalactone content frequently diverges from actual content.[2] Heavy metal and pesticide residue data for commercial kava products are lacking.safety citation needed No internationally harmonized quality standard exists; a six-point standardization plan specifying noble cultivars, 5-year harvest age, peeled roots only, aqueous extraction, maximum 250 mg kavalactones/day, and Pan-Pacific quality control has been proposed but not implemented at scale.[18]
Kava dermopathy — a reversible ichthyosis-like scaly, dry, yellowish skin discoloration — occurs in heavy chronic users.[1][32] It resolves upon dose reduction or cessation.
Regular kava use may produce false-positive results on amphetamine immunoassay urine screens; confirmatory GC-MS testing will be negative.[34]
Psychological Risks
At therapeutic and moderate doses, adverse effects are mild: gastrointestinal upset, headache, dizziness, and fatigue are the most commonly reported in clinical trials.[8] High doses produce significant sedation and motor impairment. Tudei (non-noble) cultivars produce prolonged lethargy and nausea lasting up to two days — the origin of the name "two-day kava".[2]
Kava is not hallucinogenic at standard doses, and no documented cases of kava-induced psychosis were identified in retrieved literature. A medicinal dose of 180 mg kavalactones does not impair simulated driving performance; in contrast, oxazepam 30 mg significantly reduces alertness and slows braking reaction time.[27]
Tolerance & Dependence
"Reverse tolerance" is described in traditional kava communities: regular users report requiring less kava over time, opposite to typical pharmacological tolerance.[2] The mechanism is poorly understood. Clinical trials of 8–16 weeks have not required dose escalation.[8]
Dependence risk at therapeutic and moderate doses is considered low; kava is described as non-addictive in clinical literature.[35][24] Heavy chronic use has, however, been associated with physiological dependence. One severe withdrawal case involved a 45-year-old man using both kava and kratom who presented with hallucinations, anxiety, insomnia, and muscle jerking after abrupt cessation.[9] Phenobarbital produced significant improvement; the patient was transitioned to diazepam. Isolated kava withdrawal contribution cannot be definitively separated from concurrent kratom use.
Heavy chronic users considering cessation should taper gradually. Medical supervision is recommended for long-term heavy users, and GABAergic withdrawal protocols (phenobarbital or benzodiazepine taper) may be indicated in severe cases.[9]
Drug Interactions
Benzodiazepines (alprazolam and class): Additive GABAergic sedation at distinct receptor binding sites. A documented case of coma followed combined kava and alprazolam use.[11] Concurrent use should be avoided.
Alcohol: Additive CNS depression and possible hepatotoxicity potentiation. Early hepatotoxicity case reports involved alcohol co-consumption.[15][13]
Other CNS depressants (opioids, sedative antihistamines, antipsychotics): Additive or synergistic CNS depression via multiple pathways.[1][24]
CYP2C9/CYP2C19 substrates (warfarin, phenytoin, omeprazole): In vitro inhibition demonstrated at kavalactone concentrations of 5–10 µM.[22] No controlled human interaction study confirms clinical significance at standard doses.citation needed
Hepatotoxic medications: Additive hepatotoxicity risk on mechanistic grounds. Concurrent use is contraindicated with pre-existing liver disease.
CYP3A4 substrates (midazolam, immunosuppressants, statins): Intestinal CYP3A inhibition demonstrated in animal models[36] but not confirmed at standard doses in humans.[37]
Contraindications
Pre-existing liver disease: Absolute contraindication given documented hepatotoxicity risk across preparation types.[10]
Concurrent heavy alcohol use: Absolute contraindication — additive hepatotoxicity and CNS depression.[15][13]
Concurrent benzodiazepine or GABAergic sedative use: Potentially life-threatening interaction documented.[11]
Pregnancy and lactation: Contraindicated due to insufficient safety data; kavalactones may cross the placenta based on molecular properties.[1]safety citation needed
Children and adolescents: No safety or efficacy data exist in pediatric populations.
CYP2D6 poor metabolizers: Potentially increased hepatotoxicity susceptibility.[15]
Caution is advised for users taking narrow therapeutic index medications metabolized by CYP2C9 or CYP2C19 (e.g., warfarin, phenytoin), though interaction data are limited to in vitro findings.[22]
Harm Reduction[edit]
Forms & Identification
Kava products range from traditional ground root to standardized capsules, instant powders, and concentrated liquid extracts. Quality varies enormously: labeled kavalactone content frequently diverges from actual content, and noble/tudei cultivar substitution is visually undetectable. A Certificate of Analysis (CoA) from an ISO-accredited laboratory is the most reliable verification — it should confirm kavalactone content, cultivar identity (chemotype analysis showing noble-type kavalactone ratios), absence of elevated flavokavain B, and negative mycotoxin screening. Products without third-party testing carry unquantifiable contamination risk.
Guidelines
- Start with a single shell (100–150 mL) of traditional aqueous preparation or the lowest recommended dose of a standardized product and wait 30–45 minutes before additional servings
- Use only products confirmed as noble cultivar — tudei (non-noble) varieties produce heavier sedation, nausea, and next-day lethargy lasting up to two days
- Do not combine kava with alcohol, benzodiazepines, opioids, or other CNS depressants
- If using capsules or extracts, do not exceed 250 mg total kavalactones per day without medical guidance
- Monitor for signs of liver stress (dark urine, yellowing skin or eyes, unusual fatigue, upper right abdominal pain) — discontinue immediately and seek medical evaluation if these appear
- Maintain kava-free days each week to reduce cumulative hepatic exposure
- Stay hydrated — kava has mild diuretic properties
Set & Setting
Kava is traditionally consumed in communal settings, and the sociable character of noble cultivar preparations complements group contexts. First-time users should try kava in a calm, familiar environment with experienced companions. Effects can feel subtle on initial use due to "reverse tolerance" — sensitivity typically increases over sessions, not decreases. Avoid kava before driving or operating machinery, particularly with unfamiliar products or doses. Daily use patterns should be approached with caution despite kava's low dependence profile at moderate doses.
Aftercare & integration. Post-session grogginess is common after moderate-to-heavy kava use, particularly with standardized extracts or high-dose sessions. Hydrate thoroughly before sleep and upon waking. Mild next-day fatigue is normal and typically resolves within hours.
If tudei cultivar kava was consumed (intentionally or accidentally), residual sedation and nausea may persist for 24–48 hours — rest and hydration are the primary management.
Regular users should schedule periodic liver function tests (ALT, AST, GGT) with a healthcare provider, particularly if consuming kava more than three times per week.
Recovery & Support
Kava dependence is uncommon at therapeutic doses but can develop with heavy chronic use. Abrupt cessation after sustained heavy use may produce a GABAergic withdrawal — anxiety, insomnia, tremor, and in rare cases hallucinations.[9]
Tapering: Reduce intake gradually over 2–4 weeks rather than stopping abruptly. Cut each week's dose by approximately 25%.
Medical support: Heavy chronic users experiencing withdrawal symptoms should seek medical evaluation. GABAergic withdrawal protocols (phenobarbital or benzodiazepine taper) may be required in severe cases.[9]
Resources:
- SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7)
- Alcohol and Drug Foundation (Australia): 1300 85 85 84
- FRANK (UK): 0300 123 6600
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Kava emergencies are rare at standard doses but can occur with very high doses, tudei cultivar ingestion, or dangerous combinations.
Recognizing an emergency:
- Severe sedation or unresponsiveness after kava combined with benzodiazepines, alcohol, or opioids
- Signs of acute liver injury: sudden jaundice, severe abdominal pain, dark urine, confusion
- Severe persistent vomiting preventing fluid intake
Immediate steps:
- 1. Do not leave the person alone
- 2. Place an unresponsive person in the recovery position
- 3. Call emergency services if the person is unresponsive, has difficulty breathing, or shows signs of liver distress
- 4. Do not attempt to induce vomiting
What to tell the dispatcher: Name the substance (kava), approximate amount consumed, time of ingestion, any other substances taken, and current symptoms. Good Samaritan laws exist in many jurisdictions and protect callers reporting drug-related emergencies.
No specific reversal agent exists for kava. Supportive care is the standard treatment.
Legal Status[edit]
Kava and its active kavalactones are not scheduled under any of the three principal United Nations drug control conventions: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, or the 1988 Convention Against Illicit Traffic.[38] No international treaty restriction applies to kava trade or consumption. Legal status varies significantly by jurisdiction, shaped primarily by national regulatory responses to hepatotoxicity case reports in the early 2000s. Several countries maintain outright bans, others restrict kava to regulated health products, and Pacific Island nations treat it as a legal cultural and commercial commodity.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Not a controlled substance | Sold as a dietary supplement under DSHEA (1994). FDA consumer advisory on hepatotoxicity risk issued 2002. Growing kava bar industry in Florida, California, and Pacific coast states[38] |
| Germany | Ban lifted (2024) | BfArM banned kava pharmaceuticals in 2002. Courts overturned the ban beginning circa 2013–2015.[5] Cologne Administrative Court lifted the ban definitively on June 18, 2024[6] |
| France | Banned | Outright ban maintained as of 2024, with limited exceptions for certain homeopathic preparations[39] |
| United Kingdom | Banned | No reclassification as of 2025[39] |
| Australia | Listed medicine (OTC) | TGA approved: maximum 125 mg kavalactones per solid dose, 250 mg/day maximum. Traditional import permitted for Pacific Island communities[39] |
| Canada | Restricted | Available in some natural health product formulations under NHP regulations[39] |
| Netherlands, Indonesia, Japan, South Korea | Prohibited in supplements | Banned for sale as dietary supplements[39] |
| Pacific Island nations | Legal | Legal for traditional, cultural, and commercial use. Vanuatu Kava Act 2002 governs noble cultivar export standards. Significant export commodity for Vanuatu, Fiji, and Tonga[7] |
Kavalactones are not individually scheduled in any jurisdiction. Unlike some plant preparations where active compounds are internationally controlled (e.g., DMT in ayahuasca), kava faces no structural analog-law or constituent scheduling complications.
citation needed Legal status in EU member states other than Germany and France, South American countries, and Southeast Asian non-producing countries has not been verified in retrieved literature.
references
- [1]
- [2]
- [3] ^abcdChua HC, Christensen ET, Hoestgaard-Jensen K, et al. (2016) Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism — PloS One doi:10.1371/journal.pone.0157700
- [4]
- [5] ^abcKuchta K, Schmidt M, Nahrstedt A (2015) German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics — Planta Medica doi:10.1055/s-0035-1558295
- [6]